LUXTURNA (VORETIGENE NEPARVOVEC-RZYL)
LUXTURNA (VORETIGENE NEPARVOVEC-RZYL) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: LUXTURNA; Generic name: VORETIGENE NEPARVOVEC-RZYL; Manufacturer: Spark Therapeutics, Inc..
| Brand name | LUXTURNA |
|---|---|
| Generic name | VORETIGENE NEPARVOVEC-RZYL |
| Manufacturer | Spark Therapeutics, Inc. |
| Used for | 1 INDICATIONS AND USAGE LUXTURNA (voretigene neparvovec-rzyl) is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s). LUXTURNA is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s). ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION For subretinal injection only. The recommended dose of LUXTURNA for each eye is 1.5 x 10 11 vector genomes (vg), administered by subretinal injection in a total volume of 0.3 mL. (2.1 ) Perform subretinal administration of LUXTURNA to each eye on separate days within a close interval, but no fewer than 6 days apart. ( 2.1 ) Recommend systemic oral corticosteroids equivalent to prednisone at 1 mg/kg/day (maximum of 40 mg/day) for a total of 7 days (starting 3 days befo |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08313a24-e7ce-457a-bb3f-161bc45517ee |